Edition:
United States

People: Biogen Inc (BIIB.O)

BIIB.O on Nasdaq

281.77USD
18 Aug 2017
Change (% chg)

$-2.65 (-0.93%)
Prev Close
$284.42
Open
$283.31
Day's High
$285.67
Day's Low
$281.65
Volume
814,072
Avg. Vol
1,459,887
52-wk High
$329.83
52-wk Low
$244.28

Rowinsky, Eric 

Dr. Eric K. Rowinsky, M.D. is an Independent Director of the Company. Dr. Rowinsky has served as one of our directors since 2010. He has served as President of RGenix, Inc., a privately-held life sciences company, since November 2015 and as its Executive Chairman since December 2015. From January 2012 to November 2015, Dr. Rowinsky was the Head of Research and Development and Chief Medical Officer of Stemline Therapeutics, Inc., a biotechnology company focusing on the discovery and development of therapeutics targeting cancer stem cells. Dr. Rowinsky is an Adjunct Professor of Medicine at New York University and has been an independent consultant since January 2010. Prior to that, he was the Chief Medical Officer of Primrose Therapeutics, Inc., a start-up biotechnology company focusing on the development of therapeutics for polycystic kidney disease, from August 2010 until its acquisition in September 2011. From 2005 to December 2009, he served as the Chief Medical Officer and Executive Vice President of ImClone Systems Incorporated, a life sciences company. From 1996 to 2004, Dr. Rowinsky held several positions at the Cancer Therapy & Research Center’s Institute for Drug Development, including Director of the Institute and Director of Clinical Research. During that time, he held the SBC Endowed Chair for Early Drug Development and Clinical Professor of Medicine at the University of Texas Health Science Center at San Antonio. From 1988 to 1996, Dr. Rowinsky was an Associate Professor of Oncology at the Johns Hopkins School of Medicine and on the staff of the Johns Hopkins Hospital.

Basic Compensation

Total Annual Compensation, USD 151,000
Restricted Stock Awards, USD 269,420
Long-Term Incentive Plans, USD --
All Other, USD --
Fiscal Year Total, USD 420,420

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --